Truist Securities maintained a Hold rating for Hims & Hers Health, Inc. (NYSE:HIMS), with a steady price target of $23.00. The firm’s analyst cited the U.S. Food and Drug Administration’s (FDA) recent decision to revisit the shortage of Tirzepatide and the continued authorization for compounding pharmacies to produce its compounded version as positive for the company’s prospects.
This decision is particularly relevant for Hims & Hers’ compounded GLP-1 product, which uses Semaglutide—an ingredient still on the FDA’s shortage list.
The FDA’s move comes after concerns among investors that Semaglutide would be removed from the shortage list, which could have impacted Hims & Hers’ operations. However, the recent lawsuit by the Outsourcing Facilities Association (OFA) appears to have influenced the FDA to adopt a more cautious stance on declaring the Semaglutide shortage resolved. The agency’s response to the lawsuit seems to support this more measured approach.
Truist’s analyst highlighted the uncertainty around the long-term visibility for Hims & Hers but acknowledged that the company could benefit from its compounded GLP-1 offerings in the short term. These offerings were launched recently and are now part of the broader conversation due to the FDA’s ongoing review and the litigation context.
The FDA’s decision and the legal developments surrounding the OFA lawsuit have created a dynamic situation for Hims & Hers. The company’s compounded GLP-1 offering, which is still in demand due to the shortage of Semaglutide, seems poised to continue playing a role in its market performance.
Investors and market watchers will likely continue to monitor the FDA’s actions and the outcome of the OFA lawsuit to gauge their impact on Hims & Hers’ business and stock performance. The current Hold rating reflects a wait-and-see approach, balancing the potential near-term benefits against the uncertainties that lie ahead.
In other recent news, Hims & Hers Health, Inc. has been at the center of several significant developments. The company reported a 52% year-over-year revenue increase in Q2 2024, reaching $316 million, with an adjusted EBITDA of $39 million. They also issued 976,341 Class A common shares to Nivagen Pharmaceuticals, Inc. as part of the acquisition of MedisourceRx, expanding its product offerings and market reach.
Canaccord Genuity maintained a buy rating on Hims & Hers due to the potential of its compounded GLP-1 medications amid rising obesity trends. The firm sees a promising total addressable market of approximately $6 to $8 billion. Meanwhile, Truist Securities held a neutral stance, noting the company’s inclusion in the Small-cap S&P 600 index and a lawsuit filed against the FDA.
Citi also maintained a neutral rating following the FDA’s decision to remove Tirzepatide from its shortage list, which could affect Hims & Hers’ future plans. The company launched a Service Appreciation Initiative offering discounted weight loss treatments to service members.
InvestingPro Insights
As Hims & Hers Health, Inc. (NYSE:HIMS) navigates the complex landscape of FDA decisions and market dynamics, recent financial data from InvestingPro sheds light on the company’s performance. HIMS has demonstrated impressive revenue growth, with a 50.15% increase over the last twelve months as of Q2 2024, reaching $1.07 billion. This robust growth aligns with the company’s ability to capitalize on market opportunities, such as the demand for compounded GLP-1 products mentioned in the article.
InvestingPro Tips highlight that HIMS has been profitable over the last twelve months, with analysts predicting continued profitability this year. This positive outlook is particularly relevant given the uncertain regulatory environment discussed in the article. Additionally, the company’s liquid assets exceed short-term obligations, suggesting a strong financial position to weather potential challenges or capitalize on opportunities arising from FDA decisions.
It’s worth noting that HIMS is trading at a high P/E ratio of 241.41, indicating investor optimism about future growth prospects. This valuation metric could be influenced by factors such as the company’s position in the compounded GLP-1 market and its ability to adapt to regulatory changes.
For investors seeking a more comprehensive analysis, InvestingPro offers 13 additional tips for HIMS, providing deeper insights into the company’s financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.